Answer
Yes, eribulin mesylate was associated with QT prolongation on Day 8, but not Day 1, independently of eribulin concentration in an uncontrolled, open-label ECG study of 26 patients; it should be avoided in patients with congenital long QT syndrome.
Sources for this answer
- Eribulin Eisai 0.44 mg/ml solution for injectionEisai Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 26Document updated
Sources checked